Development and synthesis of peptide with tropism to prostate-specific surface antigen

Prostate cancer is the most common cancer in men and the second major cause of cancer death in men over 50. Expression of the prostatic specific membrane antigen in the epithelial cells of the prostate gland directly underlies the development of prostate cancer in vivo. Positron emission tomography and radionuclide therapy in the diagnosis and treatment of prostate cancer is very promising. Thus, the development of radiopharmaceuticals based on peptides with tropism to PSSA is relevant. The objective of the paper is to select a peptide with tropism to prostate-specific surface antigen, and a chelator that meets the stability criteria. Materials and Methods. The cell line of LNCaP prostatic adenocarcinoma was used during the trial. Peptide synthesis was carried out on peptide synthesizer IntavisRSi. To study peptide properties, NAALADase-analysis, molecular docking and determination of IC50 values to LNCaP cell line were carried out. Results. The IC50 values for binding affinity determination were calculated for each chelator bound to the peptide studied...